1887

Abstract

Following withdrawal of immunosuppression, surfactant protein A (SP-A)-deficient and wild-type mice cleared infection in a similar manner, but exhibited significant differences in lymphocyte populations, interleukin (IL)-6 levels and chemokine expression levels. A higher percentage of lymphocytes were detected in lung lavage fluid from SP-A-deficient mice, but more CD4+ T cells were isolated from lung tissue of wild-type mice. Higher concentrations of IL-6 were detected in lavage fluid and enhanced expression of lymphotactin and RANTES were detected in the lungs of wild-type mice. Equal levels of surfactant protein D were detected in SP-A-deficient and wild-type mice and no differences were detected in markers of lung injury between the two strains of mice. Thus, SP-A does not enhance organism clearance, but does modulate the host immune response during resolution of infection.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.46190-0
2006-02-01
2019-11-21
Loading full text...

Full text loading...

/deliver/fulltext/jmm/55/2/143.html?itemId=/content/journal/jmm/10.1099/jmm.0.46190-0&mimeType=html&fmt=ahah

References

  1. Atochina, E. N., Beck, J. M., Preston, A. M. & 8 other authors ( 2004; ). Enhanced lung injury and delayed clearance of Pneumocystis carinii in surfactant protein A-deficient mice: attenuation of cytokine responses and reactive oxygen-nitrogen species. Infect Immun 72, 6002–6011.[CrossRef]
    [Google Scholar]
  2. Barry, S. M., Lipman, M. C., Deery, A. R., Johnson, M. A. & Janossy, G. ( 2002; ). Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med 3, 207–211.[CrossRef]
    [Google Scholar]
  3. Chen, W., Havell, E. A., Gigliotti, F. & Harmsen, A. G. ( 1993; ). Interleukin-6 production in a murine model of Pneumocystis carinii pneumonia: relation to resistance and inflammatory response. Infect Immun 61, 97–102.
    [Google Scholar]
  4. Elhalwagi, B. M., Zhang, M., Ikegami, M., Iwamoto, H. S., Morris, R. E., Miller, M. L., Dienger, K. & McCormack, F. X. ( 1999; ). Normal surfactant pool sizes and inhibition-resistant surfactant from mice that overexpress surfactant protein A. Am J Respir Cell Mol Biol 21, 380–387.[CrossRef]
    [Google Scholar]
  5. Gold, J. A., Hoshino, Y., Tanaka, N., Rom, W. N., Raju, B., Condos, R. & Weiden, M. D. ( 2004; ). Surfactant protein A modulates the inflammatory response in macrophages during tuberculosis. Infect Immun 72, 645–650.[CrossRef]
    [Google Scholar]
  6. Korfhagen, T. R., LeVine, A. M. & Whitsett, J. A. ( 1998; ). Surfactant protein A (SP-A) gene targeted mice. Biochim Biophys Acta 1408, 296–302.[CrossRef]
    [Google Scholar]
  7. Koval, C. E., Gigliotti, F., Nevins, D. & Demeter, L. M. ( 2002; ). Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis 35, 491–493.[CrossRef]
    [Google Scholar]
  8. LeVine, A. M., Bruno, M. D., Huelsman, K. M., Ross, G. F., Whitsett, J. A. & Korfhagen, T. R. ( 1997; ). Surfactant protein A-deficient mice are susceptible to group B streptococcal infection. J Immunol 158, 4336–4340.
    [Google Scholar]
  9. LeVine, A. M., Kurak, K. E., Bruno, M. D., Stark, J. M., Whitsett, J. A. & Korfhagen, T. R. ( 1998; ). Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol 19, 700–708.[CrossRef]
    [Google Scholar]
  10. LeVine, A. M., Gwozdz, J., Stark, J., Bruno, M., Whitsett, J. & Korfhagen, T. ( 1999; ). Surfactant protein-A enhances respiratory syncytial virus clearance in vivo. J Clin Invest 103, 1015–1021.[CrossRef]
    [Google Scholar]
  11. Limper, A. H., Offord, K. P., Smith, T. F. & Martin, W. J. ( 1989; ). Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 140, 1204–1209.[CrossRef]
    [Google Scholar]
  12. Linke, M. J., Harris, C. E., Korfhagen, T. R., McCormack, F. X., Ashbaugh, A. D., Steele, P., Whitsett, J. A. & Walzer, P. D. ( 2001; ). Immunosuppressed surfactant protein A-deficient mice have increased susceptibility to Pneumocystis carinii infection. J Infect Dis 183, 943–952.[CrossRef]
    [Google Scholar]
  13. Linke, M., Ashbaugh, A., Koch, J., Tanaka, R. & Walzer, P. ( 2005; ). Surfactant protein A limits Pneumocystis murina infection in immunosuppressed C3H/HeN mice and modulates host response during infection. Microbes Infect 7, 748–759.[CrossRef]
    [Google Scholar]
  14. McCormack, F. X. & Whitsett, J. A. ( 2002; ). The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J Clin Invest 109, 707–712.[CrossRef]
    [Google Scholar]
  15. McCormack, F. X., Gibbons, R., Ward, S. R., Kuzmenko, A., Wu, H. & Deepe, G. S. J. ( 2003; ). Macrophage-independent fungicidal action of the pulmonary collectins. J Biol Chem 278, 36250–36256.[CrossRef]
    [Google Scholar]
  16. McNeely, T. B. & Coonrod, J. D. ( 1993; ). Comparison of the opsonic activity of human surfactant protein A for Staphylococcus aureus and Streptococcus pneumoniae with rabbit and human macrophages. J Infect Dis 167, 91–97.[CrossRef]
    [Google Scholar]
  17. Morris, A., Lundgren, J. D., Masur, H., Walzer, P. D., Hanson, D. L., Frederick, T., Huang, L., Beard, C. B. & Kaplan, J. E. ( 2004; ). Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 10, 1713–1720.[CrossRef]
    [Google Scholar]
  18. Nuesch, R., Bellini, C. & Zimmerli, W. ( 1999; ). Pneumocystis carinii pneumonia in human immunodeficiency virus (HIV)-positive and HIV-negative immunocompromised patients. Clin Infect Dis 29, 1519–1523.[CrossRef]
    [Google Scholar]
  19. Sepkowitz, K. A. ( 2002; ). Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 34, 1098–1107.[CrossRef]
    [Google Scholar]
  20. Thomas, C. F. J. & Limper, A. H. ( 2004; ). Pneumocystis pneumonia. N Engl J Med 350, 2487–2498.[CrossRef]
    [Google Scholar]
  21. Thullen, T. D., Ashbaugh, A. D., Daly, K. R., Linke, M. J., Steele, P. E. & Walzer, P. D. ( 2004; ). Sensitized splenocytes result in deleterious cytokine cascade and hyperinflammatory response in rats with Pneumocystis pneumonia despite the presence of corticosteroids. Infect Immun 72, 757–765.[CrossRef]
    [Google Scholar]
  22. Van Iwaarden, J. F., Pikaar, J. C., Storm, J., Brouwer, E., Verhoef, J., Oosting, R. S., van Golde, L. M. & van Strijp, J. A. ( 1994; ). Binding of surfactant protein A to the lipid A moiety of bacterial lipopolysaccharides. Biochem J 303, 407–411.
    [Google Scholar]
  23. Walzer, P. D., LaBine, M., Redington, T. J. & Cushion, M. T. ( 1984; ). Lymphocyte changes during chronic administration of and withdrawal from corticosteroids: relation to Pneumocystis carinii pneumonia. J Immunol 133, 2502–2508.
    [Google Scholar]
  24. Walzer, P. D., Stanforth, D., Linke, M. J. & Cushion, M. T. ( 1987; ). Pneumocystis carinii: immunoblotting and immunofluorescent analyses of serum antibodies during experimental rat infection and recovery. Exp Parasitol 63, 319–328.[CrossRef]
    [Google Scholar]
  25. Wright, T. W., Johnston, C. J., Harmsen, A. G. & Finkelstein, J. N. ( 1999; ). Chemokine gene expression during Pneumocystis carinii-driven pulmonary inflammation. Infect Immun 67, 3452–3460.
    [Google Scholar]
  26. Wu, H., Kuzmenko, A., Wan, S., Schaffer, L., Weiss, A., Fisher, J. H., Kim, K. S. & McCormack, F. X. ( 2003; ). Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest 111, 1589–1602.[CrossRef]
    [Google Scholar]
  27. Zimmerman, P. E., Voelker, D. R., McCormack, F. X., Paulsrud, J. R. & Martin, W. J. ( 1992; ). 120-kD surface glycoprotein of Pneumocystis carinii is a ligand for surfactant protein A. J Clin Invest 89, 143–149.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.46190-0
Loading
/content/journal/jmm/10.1099/jmm.0.46190-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error